Medical Marijuana in Canada: A Growth Industry

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion
Source: Streetwise Reports (04/08/2026)

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.

read more >

California Biotech Co. Advances Depression Drug Breakthrough
Source: Streetwise Reports (04/07/2026)

Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.

read more >

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial
Source: Dr. Ananda Ghosh (04/07/2026)

H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.

read more >

Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough
Source: Streetwise Reports (04/02/2026)

Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.

read more >

Biotech Company Uncovers Breakthrough Canine Arthritis Treatment
Source: Streetwise Reports (03/30/2026)

Israeli co. Can-Fite BioPharma Ltd. (CANF:NYSEAmerican) teamed up with Vetbiolix to trial Piclidenoson for dogs, with Phase 2 results due Q3 2026. Yet, one analyst still rates the stock as a Hold. Read on to see why.

read more >